Recent Study Suggests Medicare Could Save $18 Billion over Next Decade by Switching from Lucentis to Avastin 
A recent article  in Health Affairs cites a new study that looked at the effects of the two drugs on patients’ vision and overall health and on Medicare spending over ten years. The study found that $18 billion could be eliminated from the Medicare Part B budget and nearly $5 billion in copayments could be saved with little impact on patient health by switching from Lucentis to Avastin.
The article notes that despite physicians prescribing Avastin off-label, good evidence exists regarding Avastin’s similar efficacy to Lucentis when used as an ophthalmologic therapy. This could become more important as FDA moves forward with their office use and repackaging guidance if the new compounding regulations limit the availability of Avastin. We will continue to provide updates in the Washington Watch.